Introduction {#s1}
============

Drug addiction is characterized by persistent drug use despite adverse consequences, perhaps in part because the instant pleasure garnered by using drugs is perceived to outweigh the long-term benefits of sobriety. Consistent with this idea, laboratory studies routinely find that individuals with substance use disorders display greater preference for smaller, more immediately available rewards (e.g. money, drugs) over larger, delayed alternatives than healthy controls ([@CIT0039]). Moreover, research indicates that those who most strongly favor the immediate options on such laboratory-based choice tasks are also most likely to relapse during attempted abstinence ([@CIT0033]; [@CIT0076]; [@CIT0038]; [@CIT0046]; [@CIT0069]; [@CIT0059]; [@CIT0061] and also see [@CIT0050]; [@CIT0035]). Nonetheless, few studies have attempted to elucidate the neural mechanisms underlying addicts' inordinate preference for immediate rewards.

Dopamine is heavily implicated in intertemporal choice (for a review, see [@CIT0072]), and indirect evidence suggests that deficient dopamine D~2~/D~3~-type receptor-mediated dopaminergic neurotransmission in the striatum may be an important contributing factor to this immediacy bias. Like steep temporal discounting, low striatal D~2~/D~3~ receptor availability is observed among individuals with substance use disorders (for a review, see [@CIT0064]), and has been linked with an increased likelihood of relapse ([@CIT0040]; [@CIT0068]). Chronic exposure to methamphetamine (MA) or cocaine induces persistent reductions in striatal D~2~/D~3~ receptor availability in rats ([@CIT0042]; [@CIT0054]) and monkeys ([@CIT0048]; [@CIT0023]), and rats treated chronically with either of these drugs exhibit greater temporal discounting than controls ([@CIT0055]; [@CIT0049]; [@CIT0057]; [@CIT0043]). Humans with attention-deficit hyperactivity disorder or obesity---two other disorders that are associated with low striatal D~2~/D~3~ receptor availability (for a review, see [@CIT0064])---also display greater temporal discounting than healthy controls (for a review, see [@CIT0004]). Greater temporal discounting has also been observed among carriers of the A1 allele of the *ANKK1* Taq1A polymorphism ([@CIT0015]), a genetic variant associated with low striatal D~2~ receptor density/binding in humans relative to A2 homozygotes ([@CIT0030]).

Although an association between low striatal D~2~/D~3~ receptor availability and steep temporal discounting has been implied, this link has not been directly evaluated. We therefore examined striatal D~2~/D~3~ receptor availability in relation to temporal discounting in research participants who met DSM-IV criteria for MA dependence and a group of healthy controls. MA-dependent individuals were selected as a group for study because case-control studies find that they display deficits in striatal D~2~/D~3~ receptor availability ([@CIT0066]; [@CIT0036]; [@CIT0068]) and exaggerated temporal discounting ([@CIT0025]; [@CIT0045]). We hypothesized that striatal D~2~/D~3~ receptor availability would be negatively correlated with discount rates among MA users, and possibly also among controls. Because tobacco use has also been linked with low striatal D~2~/D~3~ receptor availability (among males; [@CIT0017]; [@CIT0008]) and steep temporal discounting ([@CIT0039]), the association was explored as well in the control-group smokers. Because chronic MA abusers also display lower D~2~/D~3~ receptor availability than non-users in extrastriatal brain areas (London laboratory unpublished data), including several that have been implicated in intertemporal choice (for reviews, see [@CIT0009]; [@CIT0070]), exploratory analyses were performed to investigate whether extrastriatal D~2~/D~3~ receptor availability might also be negatively correlated with discount rate.

Methods {#s2}
=======

Participants {#s3}
------------

Procedures were approved by the University of California Los Angeles (UCLA) Office for Protection of Research Subjects. Participants were recruited using the Internet and local newspaper advertisements. All provided written informed consent and underwent eligibility screening using questionnaires, the Structured Clinical Interview for DSM-IV ([@CIT0019]), and a physical examination. Twenty-seven individuals who met criteria for current MA dependence but were not seeking treatment for their addiction and 27 controls completed the study. D~2~/D~3~ receptor availability data from approximately half of the MA users and controls have been reported previously ([@CIT0036]), and smaller subsets were included in other studies from our laboratory regarding D~2~/D~3~ receptor availability ([@CIT0008]; [@CIT0008]; [@CIT0077]; [@CIT0032]).

The exclusion criteria were: central nervous system, cardiovascular, pulmonary, hepatic, or systemic disease; HIV seropositive status; pregnancy; lack of English fluency; MRI ineligibility (e.g. metal implants, claustrophobia); current use of psychotropic medications; current Axis I disorder including substance abuse or dependence for any substance other than nicotine (or MA or cannabis for MA users only; all MA users met criteria for MA dependence, and 2 met criteria for cannabis dependence; substance-induced mood disorders were also not exclusionary for this group).

A diagnosis of MA dependence and a positive urine test for MA at intake were required for MA-group participants, who completed the study as inpatients at the UCLA General Clinical Research Center, and were prohibited from using any drugs (besides nicotine in cigarettes) for 4--7 days before testing. MA users completed the behavioral and imaging measures 2 days apart on average (standard deviation \[SD\] = 2.1; range: 1--11). Controls were studied on a nonresidential basis and completed the measures 22 days apart on average (SD = 28.0; range 1--111). All participants were required to provide a urine sample on each test day that was negative for amphetamine, cocaine, MA, benzodiazepines, opioids, and cannabis. Compensation was provided in the form of cash, gift certificates, and vouchers.

Delay Discounting {#s4}
-----------------

Delay discounting was assessed with the Monetary-Choice Questionnaire (MCQ; [@CIT0031]), which presents participants with 27 hypothetical choices between a smaller, immediate monetary amount and a larger, delayed alternative. Most of the participants completed the task using a paper-and-pencil format, but some completed the task on a computer (10 controls \[9 smokers\], 4 MA users); the questions were presented in the same sequence, regardless of task format.

A logistic regression was performed on the data from each participant, separately, using his/her responses to all 27 choices (coded as 0 for immediate-option and 1 for delayed-option selections) as the dependent variable, and the natural log of the equivalence k value associated with each test question as the independent variable. This k-equivalence value was the number that would equalize the immediate option with the delayed alternative, assuming the hyperbolic discounting function: V = A/(1 + kD), where V represents the perceived value of amount A made available D days in the future ([@CIT0004]). The parameter estimates from the logistic regression were used to calculate the k-equivalence value at which the function intersected 0.5 (the stochastic indifference point). This derived k value characterized the individual's discount rate ([@CIT0031]; see [@CIT0071]). Because the MCQ only probes discounting between a minimum k-equivalence of 0.0002 and a maximum of 0.25, these values were designated as the minimum and maximum k values, respectively, that could be assigned.

D~2~/D~3~ Receptor Availability {#s5}
-------------------------------

Dopamine D~2~/D~3~ receptor availability was assessed using a Siemens EXACT HR+ positron emission tomography (PET) scanner in 3D mode with \[^18^F\]fallypride as the radioligand ([@CIT0047]). Following a 7min transmission scan acquired using a rotating ^68^Ge/^68^Ga rod source to measure and correct for attenuation, PET dynamic data acquisition was initiated with a bolus injection of \[^18^F\]fallypride (\~5 mCi ± 5%, specific activity ≥ 1 Ci/μmol). Emission data were acquired in two 80min blocks, separated by a 10--20min break.

Raw PET data were corrected for decay, attenuation, and scatter, and then reconstructed using ordered-subsets expectation-maximization (3 iterations; 16 subsets), using ECAT v7.2 software (CTI PET Systems Inc.). Reconstructed data were combined into 16 images (each representing an average of 10min of dynamic data), and the images were motion-corrected using FSL McFLIRT ([@CIT0029]), and co-registered to the individual's structural MRI scan image using a six-parameter, rigid-body transformation computed with the ART software package ([@CIT0001]). Structural images were magnetization-prepared, rapid-acquisition, gradient-echo scans acquired during a separate session using a Siemens Sonata 1.5T MRI scanner. All images were registered to MNI152 space using FSL FLIRT ([@CIT0028]). Volumes of interest (VOIs) were derived from the Harvard-Oxford atlases transformed into individual native space, or defined using FSL FIRST ([@CIT0001]). VOIs of the functional striatal subdivisions were created as described previously ([@CIT0041]).

Time-activity data within VOIs were imported into the PMOD 3.2 kinetic modeling analysis program (PMOD Technologies Ltd.), and time-activity curves were fit using the simplified reference tissue model 2 (SRTM2; [@CIT0074]). The cerebellum (excluding the vermis) was used as the reference region ([@CIT0065]). The rate constant for transfer of the tracer from the reference region to plasma (*k* ~2~′) was computed as the volume-weighted average of estimates from receptor-rich regions (caudate and putamen), calculated using the simplified reference tissue model ([@CIT0034]), as suggested by [@CIT0026]. Time-activity curves were re-fit using SRTM2 ([@CIT0074]), with the computed *k* ~2~′ value applied to all brain regions. Regional binding potential referred to non-displaceable binding, calculated as BP~ND~ = (*R* ~1~(*K* ~2~′ / *K* ~2a~) − 1), where *R* ~1~ = *K* ~1~/*K* ~1~′ is the ratio of tracer-delivery parameters for the tissue of interest and reference tissue, and *k* ~2a~ is the effective rate parameter for transfer of tracer from the tissue of interest to the plasma ([@CIT0044]; [@CIT0037]; [@CIT0027]). Volume-weighted bilateral averages of all VOIs were used for analyses.

Statistical Analyses {#s6}
--------------------

Continuous variables were assessed for homogeneity of variance across groups using Levene's tests. Demographic variables were examined for group differences using two-tailed independent- samples *t*-tests, Mann-Whitney *U*-tests, or Fisher's exact tests, as appropriate. Group differences in discount rate and BP~ND~ were tested using separate independent samples *t*-tests, and potential confounding variables were assessed as covariates. As expected, the distribution of discount rates was positively skewed. Because a natural log transform yielded a more normal distribution, ln(k) was used for analyses. The threshold for statistical significance was set at α = 0.05 for all analyses. One-tailed *p*-values are reported for analyses where a specific directional effect was predicted (e.g. higher discount rate and lower BP~ND~ in MA users on average relative to non-users, negative relationships between BP~ND~ and discount rate).

Exploratory analyses were also carried out to investigate whether discount rate is negatively correlated with BP~ND~ in extrastriatal regions. These analyses were restricted to regions that exhibit appreciable \[^18^F\]fallypride BP~ND~ (arbitrarily defined as \>0.5; see [Table 2](#T2){ref-type="table"}).

Results {#s7}
=======

Participant Characteristics {#s8}
---------------------------

The groups included similar proportions of males and females (*p* = 0.414), and did not differ in age (*p* = 0.386); however, MA users averaged significantly fewer years of formal education than controls (*p* = 0.015; [Table 1](#T1){ref-type="table"}). The majority of participants in both groups were white (MA group: 23 white \[6 Hispanic/Latino\], 2 Asian, 2 other; controls: 22 white \[5 Hispanic/Latino\], 1 black, 2 Asian, 1 Native American, 1 other). Most of the MA users, but only approximately half of the controls, were smokers (*p* = 0.018); among the smokers, the proportions of males and females were similar across groups. On average, MA users reported using MA for 9.1 years, and on 21.4 of the 30 days before enrolling in the study, with 2.7 grams used in the preceding week.

###### 

Characteristics of Research Participants

  Group                    Controls (*n* = 27)   MA users (*n* = 27)
  ------------------------ --------------------- ---------------------
  Sex (M/F)                16/11                 12/15
  Age (years)              35.4±8.8 (19--51)     33.3±9.3 (19--48)
  Education (years)        14.2±2.2 (8--18)      12.8±1.9 (9--16)\*
  No. daily tobacco        8/6                   11/12\*
  smokers (M/F)                                  
  Cigarettes per day       12.9±4.9 (8--20)      11.5±9.6 (1--40)
  (daily smokers only)                           
  Years smoking            19.1±11.4 (3--36)     17.4±9.8 (2--35)
  (daily smokers only)                           
  FTND score               3.5±2.1 (0--8)        2.7±2.4 (0--9)
  (daily smokers only)                           
  Duration of regular MA   N/A                   9.1±6.8 (1.5--24)
  use (years)                                    
  Frequency of MA use      N/A                   21.4±7.1 (5--30)
  (days in last 30 days)                         
  Intensity of MA use      N/A                   2.7±2.7 (0.6--14.5)
  (grams in last week)                           

Data are presented as mean ± SD (range), except for sex and smoking status.

*FTND:* Fagerström Test for Nicotine Dependence

(possible range: 0 \[low\] - 10 \[high\]; Heatherton et al., 1991)

\*Significant group difference, *p* \< .05

Delay Discounting {#s9}
-----------------

MA users tended to discount delayed options more steeply than controls \[ln(k) means ± standard error of the mean (SEM): MA users = -3.52±0.25, controls = -4.08±0.33; *t* ~52~ = 1.34, *p* = 0.094, Cohen's *d* = 0.36\]. Neither sex (*p* = 0.969), age (*p* = 0.215), smoking status (i.e. current smoker; *p* = 0.301), nor years of education (*p* = 0.536) independently predicted discount rate when controlling for group; however, task format (i.e. administration on paper or a computer) emerged as an extraneous predictor of discount rate (*p* = 0.027), with the computerized version associated with steeper discounting. After controlling for task format, the group difference in discounting reached statistical significance (*F* ~1,51~ = 3.70, *p* = 0.030, *η* ~*p*~ ^2^ = 0.068); the group difference was nearly significant when the two MA users who met criteria for cannabis dependence were excluded from analyses (*F* ~1,49~ = 2.81, *p* = 0.050, *η* ~*p*~ ^2^ = 0.054). As expected, control-group tobacco smokers tended to discount delayed options more steeply (-3.79±0.46) than nonsmokers (-4.39±0.48), but this difference was not significant when controlling for task format (*p* = 0.359, *η* ~*p*~ ^2^ = 0.006). Discount rates did not differ substantially between either male (-3.59±0.58) and female (-4.06±0.66) smokers or non-smokers (males: -4.40±0.70; females: -4.37±0.88) in the control group or male (-3.65±0.38) and female (-3.42±0.34) MA users when controlling for task format (all *p* \> 0.36, *η* ~*p*~ ^2^ \< 0.01).

Discount rate was not clearly related to years of regular MA use (*r* = 0.052, *p* = 0.796), days of MA use in the 30 days prior to study enrollment (*r* = -0.018, *p* = 0.928), or grams of MA used in the week prior to enrollment (*r* = -0.044, *p* = 0.830) among MA users, or to Fagerström Test for Nicotine Dependence (FTND; [@CIT0024]) scores (*r* = 0.075, *p* = 0.800), number of years smoking (*r* = 0.043, *p* = 0.884), or cigarettes per day (*r* = 0.325, *p* = 0.258) among control-group tobacco smokers.

Striatal D~2~/D~3~ Receptor Availability {#s10}
----------------------------------------

BP~ND~ was significantly lower in the striata of MA users than controls (means ± SEM: MA users = 17.13±0.57, controls = 20.15±0.70; *t* ~52~ = 3.35, *p* = 0.0005, Cohen's *d* = 0.91). When controlling for participant group, striatal BP~ND~ was not independently predicted by years of education (*p* = 0.208), but it was independently predicted by age (*p* \< 0.0005; BP~ND~ decreased as age increased), sex (*p* = 0.010; lower among males), and smoking status (*p* = 0.012; lower among smokers). A stepwise regression, controlling for group, indicated that age was the best predictor of striatal BP~ND~, and neither sex nor smoking status significantly improved the predictivity of the model including group and age. The group difference in BP~ND~ remained significant after controlling for age (*F* ~1,51~ = 21.37, *p* \< 0.0005, *η* ~*p*~ ^2^ = 0.295), and when the two MA users who met criteria for cannabis dependence were excluded from analyses (*F* ~1,49~ = 19.66, *p* \< 0.0005, *η* ~*p*~ ^2^ = 0.286). Although striatal BP~ND~ was slightly lower among control-group smokers (18.72±1.07) than non-smokers (21.69±0.70), this difference was not significant when controlling for age (*p* = 0.276, *η* ~*p*~ ^2^ = 0.015). Among controls, when controlling for age, striatal BP~ND~ was significantly lower in male (16.55±1.20) than female (21.62±1.15) smokers (*F* ~1,11~ = 9.70, *p* = 0.005, *η* ~*p*~ ^2^ = 0.469), but did not differ substantially between male (20.84±1.02) and female (23.05±0.36) nonsmokers (*p* = 0.144, *η* ~*p*~ ^2^ = 0.112). Striatal BP~ND~ was only marginally lower among male (16.52±0.63) than female (17.62±0.90) MA users when controlling for age (*p* = 0.478, *η* ~*p*~ ^2^ \< 0.0005).

Among MA users, striatal BP~ND~ was significantly negatively correlated with years of regular MA use (*r* = -0.404, *p* = 0.036), but not with days of MA use in the 30 days prior to study enrollment (*r* = -0.270, *p* = 0.172) or grams of MA used in the week prior to enrollment (*r* = -0.222, *p* = 0.266) when controlling for age. Among control-group tobacco smokers, striatal BP~ND~ tended to be negatively correlated with FTND score (*r* = -0.502, *p* = 0.068), but not with number of years smoking (*r* = -0.285, *p* = 0.322) or cigarettes per day (*r* = -0.286, *p* = 0.322) when controlling for age.

Relationship Between Delay Discounting and Striatal D~2~/D~3~ Receptor Availability {#s11}
-----------------------------------------------------------------------------------

### Combined Sample {#s12}

A significant negative correlation between discount rate and striatal BP~ND~ was found when the data from both groups of participants were combined (*r* = -0.291, *p* = 0.016), with BP~ND~ explaining 8.5% of the variance in discount rates across the pooled sample. In post hoc analyses, negative relationships were seen in all three striatal subdivisions (limbic striatum \[LST\]: *r* = -0.217, *p* = 0.057; associative striatum \[AST\]: *r* = -0.298, *p* = 0.014; sensorimotor striatum \[SMST\]: *r* = -0.258, *p* = 0.030), but only the correlation in the AST remained significant following correction for multiple comparisons using the Holm-Bonferroni method. Similar results were obtained with age-adjusted BP~ND~ values (whole striatum: *r* = -0.251, *p* = 0.033; LST: *r* = -0.171, *p* = 0.108; AST: *r* = -0.259, *p* = 0.029; SMST: *r* = -0.212, *p* = 0.062; age-adjusted values were calculated by adding the residual values obtained by regressing BP~ND~ on age in the combined sample to the sample mean for each participant). Partial correlations indicated that controlling for task format and the number of days elapsed between measures did not substantially alter the relationships between discount rate and striatal BP~ND~ (unadjusted BP~ND~ values: *r* ~partial~ = -0.223, *p* = 0.058; *r* ~partial~ = -0.152, *p* = 0.144; *r* ~partial~ = -0.223, *p* = 0.058; *r* ~partial~ = -0.189, *p* = 0.092; age-adjusted BP~ND~ values: *r* ~partial~ = -0.187, *p* = 0.095; *r* ~partial~ = -0.106, *p* = 0.230; *r* ~partial~ = -0.185, *p* = 0.097; *r* ~partial~ = -0.145, *p* = 0.155 for the whole striatum, LST, AST, and SMST, respectively); none of the partial correlation coefficients differed significantly from the respective bivariate coefficients (all *p* \> 0.68).

Sobel tests indicated that striatal BP~ND~ did not mediate the group difference in discount rate, regardless of whether age-adjusted BP~ND~ values were used, and this did not depend on task format (all *p* \> 0.29). Analogous analyses yielded similar results in each of the three striatal functional subdivisions (all *p* \> 0.23).

### MA Users {#s13}

Discount rate was significantly negatively correlated with striatal BP~ND~ (*r* = -0.342, *p* = 0.041), which explained 12% of the variance in discount rate across MA users ([Figure 1](#F1){ref-type="fig"}). Negative relationships were seen in all three striatal subdivisions (LST: *r* = -0.194, *p* = 0.166; AST: *r* = -0.322, *p* = 0.050; SMST: *r* = -0.330, *p* = 0.046; [Figure 2](#F2){ref-type="fig"}), but none reached significance after correction for multiple comparisons (Holm-Bonferroni method). Similar results were obtained with age-adjusted BP~ND~ values (whole striatum: *r* = -0.321, *p* = 0.052; LST: *r* = -0.153, *p* = 0.223; AST: *r* = -0.307, *p* = 0.060; SMST: *r* = -0.324, *p* = 0.049). Partial correlations indicated that controlling for task format and the number of days elapsed between measures did not substantially alter the relationships between discount rate and striatal BP~ND~ (unadjusted BP~ND~ values: *r* ~partial~ = -0.333, *p* = 0.052; *r* ~partial~ = -0.217, *p* = 0.149; *r* ~partial~ = -0.305, *p* = 0.069; *r* ~partial~ = -0.329, *p* = 0.054; age-adjusted BP~ND~ values: *r* ~partial~ = -0.276, *p* = 0.091; *r* ~partial~ = -0.152, *p* = 0.235; *r* ~partial~ = -0.248, *p* = 0.116; *r* ~partial~ = -0.281, *p* = 0.087 for the whole striatum, LST, AST, and SMST, respectively); none of the partial correlation coefficients differed significantly from the respective bivariate coefficients (all *p* \> 0.82).

![Regression lines illustrate correlations between delay discounting \[represented as the natural log of each individual's discount rate; ln(k)\] and striatal dopamine D~2~/D~3~ receptor availability (indexed by \[^18^F\]fallypride non-displaceable binding potential \[BP~ND~\], unadjusted) in whole striata of methamphetamine (MA) users and non-user controls. Pearson product-moment correlation coefficients are shown (*r* values).](ijnppy_pyu119_f0001){#F1}

![Regression lines illustrate correlations between delay discounting \[represented as the natural log of each individual's discount rate; ln(k)\] and striatal dopamine D~2~/D~3~ receptor availability (indexed by \[^18^F\]fallypride non-displaceable binding potential \[BP~ND~\], unadjusted) in the striatal functional subdivisions of methamphetamine (MA) users and non-user controls. Pearson product-moment correlation coefficients are shown (*r* values).](ijnppy_pyu119_f0002){#F2}

### Controls {#s14}

Discount rate tended to be negatively correlated with striatal BP~ND~ among controls, but this relationship did not reach statistical significance in either the whole striatum (*r* = -0.179, *p* = 0.185; [Figure 1](#F1){ref-type="fig"}) or any of the striatal subdivisions (LST: *r* = -0.158, *p* = 0.215; AST: *r* = -0.209, *p* = 0.147; SMST: *r* = -0.142, *p* = 0.240; [Figure 2](#F2){ref-type="fig"}). Similar results were obtained with age-adjusted BP~ND~ values (whole striatum: *r* = -0.100, *p* = 0.310; LST: *r* = -0.074, *p* = 0.356; AST: *r* = -0.130, *p* = 0.260; SMST: *r* = -0.050, *p* = 0.401). There was no indication that discount rate was more strongly correlated with striatal BP~ND~ in smokers than nonsmokers (data not shown). Partial correlations indicated that controlling for task format and the number of days elapsed between measures did not substantially alter the relationships between discount rate and striatal BP~ND~ (unadjusted BP~ND~ values: *r* ~partial~ = -0.025, *p* = 0.453; *r* ~partial~ = -0.014, *p* = 0.473; *r* ~partial~ = -0.044, *p* = 0.418; *r* ~partial~ = -0.006, *p* = 0.490; age-adjusted BP~ND~ values: *r* ~partial~ = 0.018, *p* = 0.465; *r* ~partial~ = 0.028, *p* = 0.447; *r* ~partial~ = 0.001, *p* = 0.499; *r* ~partial~ = 0.040, *p* = 0.425 for the whole striatum, LST, AST, and SMST, respectively); none of the partial correlation coefficients differed significantly from the respective bivariate coefficients (all *p* \> 0.56).

Tests comparing the slopes of the correlations revealed no significant group differences with respect to the whole striatum or any of the functional subdivisions (all *p* \> 0.30).

Exploratory Analyses in Extrastriatal Regions {#s15}
---------------------------------------------

Negative relationships between discount rate and BP~ND~ were found in all of the extrastriatal regions of MA users ([Table 2](#T2){ref-type="table"}). Notably, among MA users, correlations at *p* \< 0.05 were found in the midbrain, anterior cingulate cortex (ACC), and thalamus. In the combined sample, correlations at *p* \< 0.05 were found in the amygdala, hippocampus, and ACC. No correlations at *p* \< 0.05 were found in extrastriatal VOIs among controls. None of the correlations were significant following correction for multiple comparisons using the Holm-Bonferroni method.

###### 

Exploratory Correlational Analyses

                    Combined sample (*N* = 54)   Controls (*n* = 27)   MA users (*n* = 27)                                                                               
  ----------------- ---------------------------- --------------------- --------------------- --------- -------- --------- -------- --------- -------- --------- -------- ---------
  Amygdala          -0.302                       (0.013)               -0.264                (0.027)   -0.279   (0.080)   -0.205   (0.152)   -0.275   (0.083)   -0.251   (0.103)
  Hippocampus       -0.278                       (0.021)               -0.236                (0.043)   -0.220   (0.135)   -0.137   (0.248)   -0.295   (0.068)   -0.322   (0.051)
  Globus pallidus   -0.181                       (0.096)               -0.131                (0.173)   -0.052   (0.398)   0.036    (0.570)   -0.303   (0.062)   -0.283   (0.076)
  Thalamus          -0.194                       (0.080)               -0.137                (0.161)   -0.065   (0.374)   0.044    (0.586)   -0.334   (0.045)   -0.305   (0.061)
  Midbrain          -0.078                       (0.287)               -0.039                (0.388)   0.136    (0.750)   0.188    (0.826)   -0.376   (0.027)   -0.381   (0.025)
  mOFC              -0.210                       (0.064)               -0.149                (0.141)   -0.235   (0.119)   -0.098   (0.313)   -0.168   (0.202)   -0.133   (0.254)
  ACC               -0.270                       (0.024)               -0.228                (0.049)   -0.217   (0.138)   -0.099   (0.311)   -0.368   (0.030)   -0.372   (0.028)
  Insula            -0.164                       (0.118)               -0.086                (0.269)   -0.093   (0.323)   0.072    (0.639)   -0.288   (0.073)   -0.314   (0.055)

Data are presented as Pearson correlation coefficients (*p* value; one-tailed, uncorrected).

BP~ND~ age-adjustments made at the combined sample level.

*mOFC*: medial orbitofrontal cortex; *ACC:* anterior cingulate cortex

Tests comparing the slopes of the correlations revealed a significant group difference with respect to the midbrain (unadjusted BP~ND~ values: *p* = 0.076; age-adjusted BP~ND~ values: *p* = 0.041), but the slopes of the correlations between ln(k) and BP~ND~ were not significantly different between controls and MA users with respect to any of the other brain regions examined in exploratory analyses (all other *p* \> 0.19).

Discussion {#s16}
==========

In line with previous reports, MA users displayed lower striatal D~2~/D~3~ receptor availability ([@CIT0066]; [@CIT0036]; [@CIT0068]) and higher discount rates ([@CIT0025]; [@CIT0045]) than controls, on average. As hypothesized, discount rate was significantly negatively correlated with striatal D~2~/D~3~ receptor availability in the combined sample and among MA users alone. Although the slopes of the striatal correlations were not significantly different between controls and MA users, the relationship did not reach statistical significance among controls alone. Exploratory analyses revealed negative relationships between discount rate and D~2~/D~3~ receptor availability in every extrastriatal region examined among MA users, but none retained significance following correction for multiple comparisons.

While substantial evidence implicates dopamine as a key determinant of intertemporal choice (for reviews, see [@CIT0053]; [@CIT0072]), this study is the first to link temporal discounting directly with a measure of dopamine signaling capacity. The findings indicate that deficient D~2~/D~3~ receptor availability may contribute to steep temporal discounting among individuals with substance use disorders, attention-deficit hyperactivity disorder, or obesity (for a review, see [@CIT0004]), and carriers of the A1 allele of the *ANKK1* Taq1A polymorphism ([@CIT0015]). This reasoning is supported by reports that rats treated chronically with MA or cocaine display evidence of greater discounting of delayed rewards than saline-treated rats ([@CIT0055]; [@CIT0049]; [@CIT0057]; [@CIT0043]), as both of both of these stimulants induce persistent reductions in striatal D~2~/D~3~ receptor availability in rats ([@CIT0042]; [@CIT0054]) and monkeys ([@CIT0048]; [@CIT0023]) following chronic exposure.

The results are also compatible with the literature concerning the neuroanatomical substrates of intertemporal choice. There was evidence of correlations involving several brain regions that have been implicated by functional neuroimaging and lesion studies as playing a role in selecting between immediate and delayed rewards: e.g. the midbrain, dorsal striatum, globus pallidus, thalamus, amygdala, hippocampus, ACC, and insula (for reviews, see [@CIT0053]; [@CIT0070]). The prefrontal cortex (PFC) is critically important for the ability to resist temptation for instant gratification in order to achieve long-term goals ([@CIT0022]), and striatal D~2~/D~3~ receptor availability modulates PFC activity when goal-directed choices are made ([@CIT0032]). Moreover, D~2~/D~3~ receptor availability in the putamen has been shown to be negatively correlated with glucose metabolism in the orbitofrontal cortex, which is implicated in delaying gratification ([@CIT0022]), especially among MA users ([@CIT0066]).

Choosing a smaller, more immediately available reward over a larger, more delayed alternative can be considered as an impulsive choice. However, while striatal D~2~/D~3~ receptor availability has been shown to be negatively correlated with trait impulsivity among MA users (i.e. total score on the Barratt Impulsiveness Scale v.11; BIS-11; [@CIT0036]), there was no evidence that BIS-11 total scores were correlated with discount rates in this sample of participants (data not shown). Still, as expected, total BIS-11 scores were robustly higher among MA users than controls on average in this sample, and were negatively correlated with striatal D~2~/D~3~ receptor availability when controlling for age in the combined sample (data not shown). This result implies that even though both trait impulsivity and temporal discounting are related to striatal D~2~/D~3~ receptor availability, they represent at least partially separable constructs.

One limitation of this study is that \[^18^F\]fallypride has comparably high affinity for both D~2~ and D~3~ dopamine receptors ([@CIT0016]; [@CIT0003]), particularly as levels of D~3~ receptors may be higher than once estimated in multiple brain regions, including the striatum ([@CIT0062], [@CIT0063]). Nevertheless, several lines of research suggest that individuals with substance use disorders, including MA users ([@CIT0006]), have higher densities of D~3~ receptor levels in striatal and extrastriatal brain regions than those who do not frequently abuse drugs ([@CIT0052]). Thus, it seems probable that the lower \[^18^F\]fallypride BP~ND~ among MA users primarily reflects lower D~2~ receptor availability in this group compared to controls. An additional limitation includes the possibility of competition with endogenous dopamine influencing \[^18^F\]fallypride BP~ND~ ([@CIT0011]; [@CIT0010]). That IQ was not assessed is also a limitation, because IQ has been found to be significantly correlated with delay discounting ([@CIT0014]), and a group difference in the former could therefore overshadow the true group difference in the latter.

There are also some caveats that should be considered when interpreting the results of this study. First, the MCQ has limited ability to provide precise estimates of discount rates for individuals who discount very steeply. That is, the choice items only probe preference up to a maximum k-equivalence value of 0.25, and this value was assigned as a conservative estimate of discount rate to individuals whose calculated k value was predicted to exceed this value (3 controls, 2 MA users). Second, BP~ND~ values were highly correlated across all VOIs examined in both groups of participants, which limits the ability to draw conclusions regarding the relative importance of D~2~/D~3~ receptor availability in specific brain regions to discount rate. Finally, as there is some evidence that abstinence from drugs can increase temporal discounting among addicted individuals ([@CIT0018]), it is possible that abstinence from MA may have amplified the difference in discount rate between MA users and controls.

The results of this study may help to explain why low striatal D~2~/D~3~ receptor availability is associated with poor treatment response among individuals with MA dependence ([@CIT0068]) and cocaine dependence ([@CIT0040]). This view seems reasonable given that steep temporal discounting has also been linked with poor treatment response among cocaine-dependent individuals ([@CIT0069]), and predicts relapse among smokers ([@CIT0033]; [@CIT0076]; [@CIT0038]; [@CIT0046]; [@CIT0059]). The present results lend empirical support to a theoretical model in which [@CIT0064] propose that, "low D~2~ receptor levels and dopamine transmission in the ventral striatum lead to impulsive behavior, including the choice for smaller, immediate rewards over larger, but delayed or more effortful, rewards, which may represent an underlying behavioral pattern in addiction." Consistent with this model, we found evidence of a negative correlation between discount rate and D~2~/D~3~ receptor availability in the limbic striatal subdivision (primarily the ventral striatum). The correlation in the limbic striatum did not reach statistical significance, possibly due to the high D~3~/D~2~ receptor ratio in this region ([@CIT0052]) and partial volume effects.

An important question for future research is to determine whether interventions that increase D~2~/D~3~ receptor availability can reduce temporal discounting, at least among those with low D~2~/D~3~ receptor availability. Pharmacological interventions could prove useful to this end. For example, varenicline increases striatal D~2~/D~3~ receptor availability in rats ([@CIT0012]), and in a study of human smokers, males (but not females) treated with varenicline showed lower temporal discounting than placebo-treated controls ([@CIT0002]). This finding is compelling considering that dorsal striatal D~2~/D~3~ receptor availability is lower in male (but not female) smokers compared to nonsmoker controls ([@CIT0008]). There also is evidence that rimonabant increases striatal D~2~/D~3~ receptor availability ([@CIT0013]), and can decrease discounting of delayed rewards in rats ([@CIT0007], also see [@CIT0051]; [@CIT0073]). Nonpharmacological approaches may be useful as well, as there is preliminary evidence that intensive exercise can increase striatal D~2~/D~3~ receptor availability in MA-dependent individuals ([@CIT0032]) and patients with early-stage Parkinson's disease ([@CIT0020]). Similarly, in a mouse model of Parkinson's disease, higher striatal D~2~/D~3~ receptor availability and D~2~ receptor expression was noted among those exposed to high-intensity exercise relative to non-exercising controls ([@CIT0067]).

Establishing a causal link between D~2~/D~3~ receptor availability and temporal discounting is likely to have significant clinical implications. This is because there is evidence that interventions that reduce temporal discounting are useful for treating disorders that are associated with both steep discounting and low striatal D~2~/D~3~ receptor availability. For instance, contingency management decreases discounting among cocaine-dependent individuals ([@CIT0035]) and smokers ([@CIT0075]), and methylphenidate decreases discounting in children with attention-deficit hyperactivity disorder ([@CIT0060]). More importantly, greater reductions in discounting predict a greater likelihood of protracted abstinence among cocaine users ([@CIT0005]) and smokers ([@CIT0058]). Thus, if a causative link between D~2~/D~3~ receptor availability and temporal discounting is established, it may lead to the development of novel D~2~/D~3~-targeted interventions which could be used to more effectively treat a variety of disorders.

In conclusion, the results of this study indicate that low D~2~/D~3~ receptor availability is associated with steep temporal discounting. This link may explain why some individuals choose to continue using drugs despite knowledge of their future negative consequences, and could help to guide strategies for treating substance abuse and other psychiatric disorders.
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